Vermillion is enabling the next step in biotechnology -- deciphering proteins. The company is using a process called translational proteomics to develop diagnostic tests that take multiple protein biomarkers into account, thus making the tests more sensitive and test results more specific. Its development efforts target therapeutic areas such as oncology, hematology, cardiology, and women's health. It is working on some tests with Quest Diagnostics (which owns a minority stake in Vermillion) and has additional collaborations with academic and research institutions such as Johns Hopkins and M.D. Anderson. Vermillion emerged from Chapter 11 bankruptcy protection in early 2010.